Source: European Medicines Agency (EU) Revision Year: 2020 Publisher: L. Molteni & C. dei F.lli Alitti Soc.Es.S.p.A, Strada Statale 67, 50018 Scandicci (Firenze), Italy
Sixmo 74.2 mg implant.
| Pharmaceutical Form |
|---|
|
Implant. White/Off-white to pale yellow, rod-shaped implant, 26.5 mm long and 2.4 mm in diameter. |
Each implant contains buprenorphine hydrochloride equivalent to 74.2 mg of buprenorphine.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Buprenorphine |
Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the ÎŒ (mu) and Îș (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the ÎŒ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence. |
| List of Excipients |
|---|
|
Ethylene vinyl acetate copolymer |
Each Sixmo implant is packaged individually into a PET/LDPE/Alu/LDPE-peelable foil laminate sachet.
Implant kit: 4 Sixmo implants with 1 applicator.
L. Molteni & C. dei F.lli Alitti Soc.Es.S.p.A, Strada Statale 67, 50018 Scandicci (Firenze), Italy
EU/1/19/1369/001
20 June 2019
| Drug | Countries | |
|---|---|---|
| SIXMO | Austria, Estonia, Spain, Finland, France, Croatia, Ireland, Lithuania, Poland, Romania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
